- 864-MY-RESET
- Inquiries@EXOPYR.com
Introducing Extinguish Inflammation® 60, EXOPYR’s patent-pending, four-dimension inflammation program. Designed for people who want a coordinated approach, it brings clinical evaluation, selected interventions, and measurement at baseline, approximately Day 30, and Day 60 into one plan.
Developed by Dr. Justin Mandel, DOM, EXOPYR draws on a clinical journey that began in 1997 and includes approximately 70,000 treatments personally performed. His experience led him to develop EXOPYR’s four-dimension framework for understanding inflammation as a coordinated biological system.
Exopyr’s Extinguish Inflammation® program fuses medical precision with the refinement of concierge care.
The inaugural clinical cohort is being organized in Florida. Enrollment will depend on physician availability and clinical capacity.
* The 2025 Nobel Prize recognized general immunology research on immune regulation, not research on EXOPYR. That research broadly supports a systems-based view of inflammation, the same premise behind EXOPYR’s framework, but it does not test, validate, or endorse this specific program.
Modern immunology increasingly recognizes that inflammation emerges from coordinated interactions among immune regulation, cellular signaling, metabolism, and tissue repair. When those systems lose coordination, inflammation can persist long after its original purpose has ended.
EXOPYR was designed around that systems perspective. Its four-dimension framework organizes clinical information and selected interventions across systemic, genetic, cellular, and repair processes. The program uses laboratory measurements over time to evaluate an individual’s response. EXOPYR is preparing its inaugural physician-led cohort in Florida; clinical evaluations will begin when a physician authorized to care for Florida clients is in place.
The inaugural clinical cohort is being organized in Florida. Enrollment will depend on physician availability and clinical capacity.
Long before recent Nobel-recognized discoveries advanced our understanding of immune regulation, EXOPYR was developed around a simple clinical observation: inflammation behaves as a coordinated biological system, not a collection of isolated pathways.
Over more than two decades of clinical practice, that observation evolved into a structured four-dimension framework for understanding how inflammation affects the body. Subsequent advances in modern immunology, including Nobel-recognized discoveries in immune regulation, have provided additional scientific support for viewing inflammation as a coordinated biological process rather than a series of disconnected events.
That philosophy guides every EXOPYR program through objective biomarker monitoring and a structured framework designed to measure biological change over time, with EXOPYR physician-directed oversight being added as our clinical network is finalized.
The Four Dimensions of Biological Coordination
Systemic
Supporting balance across the body’s interconnected inflammatory systems.
Genetic
Genetic — Considering inherited biological predispositions that may influence inflammatory and metabolic regulation.
Cellular
Supporting healthy cellular function and the body’s natural antioxidant defenses.
Repair
Considering the biological processes involved in recovery, resilience, and repair.
These statements have not been evaluated by the FDA. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
Because true precision care isn’t measured by how many symptoms disappear. It’s measured by how your biology changes.
The inaugural clinical cohort is being organized in Florida. Enrollment will depend on physician availability and clinical capacity.
True precision care begins where standard medicine stops. Every nutraceutical intervention, every protocol, and every test is designed to support measurable biological change – from inflammatory balance to cellular support.
Most wellness programs focus on managing symptoms. We measure biological data.
At the heart of EXOPYR® is a four-dimension framework supported by selected laboratory measurements. The standard panel helps establish a baseline and assess change over time; it does not directly measure every process within all four dimensions. Genetic testing is not included in the standard assessment or 60-day program. Relevant inherited predispositions are considered through clinical history and existing information where appropriate.
Because true health isn’t a trend – it’s a measurable evolution.
Every program begins with EXOPYR Core Panel Lab™ biomarker testing - objective, measurable data that defines your baseline and quantifies your results.
EXOPYR is building a national clinician advisory network to review cases and ensure medical precision and safety as we scale.
Our proprietary protocol is designed to support the body's inflammatory response across four biological levels - systemic, cellular, genetic, and repair.
From initial evaluation through the Day 30 and Day 60 reviews, EXOPYR coordinates the clinical, laboratory, nutrition, and program logistics in one guided experience.
Extinguish Inflammation® 60 is EXOPYR’s patent-pending, 60-day program organized around four interconnected biological levels: systemic, genetic, cellular, and repair.
The program is designed around three measurement points: a baseline evaluation, a midpoint reassessment around Day 30, and a completion review around Day 60. Laboratory findings are considered alongside clinical history, symptoms, nutrition, and other relevant information to evaluate the response and guide next steps.
EXOPYR is preparing its inaugural Florida physician-led cohort. Once clinical enrollment begins, a physician authorized to care for clients in Florida will perform the medical evaluation and determine whether the program is appropriate for each client.
These statements have not been evaluated by the FDA. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
Extinguish Inflammation® 60 has a defined 60-day structure, three planned measurement points, and a coordinated clinical framework. As the inaugural cohort begins, EXOPYR intends to assess program delivery and report outcomes with appropriate context.
This avoids presenting program design as patient impact before the first cohort produces data.
Every client begins a guided process designed for clarity, ease, and measurable results.
| Stage | Focus | Experience |
|---|---|---|
| Interest | Florida founding cohort | Receive availability and evaluation details before deciding whether to proceed |
| Initial evaluation | History and baseline testing | Clinical review and selected laboratory measurements establish a starting point |
| Program decision | Individual recommendation | If appropriate, review the proposed 60-day plan and its full cost before enrollment |
| Midpoint | Approximately Day 30 | Repeat selected measurements and review the response |
| Completion | Approximately Day 60 | Compare results with baseline and discuss appropriate next steps |
At EXOPYR, we help forward-thinking companies safeguard their most valuable asset — their people. Our Extinguish Inflammation Corporate Reset is designed for executives, leadership teams, and high-performance employees who demand more than traditional wellness programs.
When executives perform at their peak, companies thrive. EXOPYR partners with leadership teams to optimize clarity, energy, and performance through measurable inflammation control.
This isn’t a one-size-fits-all health perk. It’s a lab-verified, doctor-developed precision program that examines inflammatory and related metabolic markers as part of a broader evaluation of executive health.
“When performance and clarity matter most, inflammation is the silent variable that determines both.”
Dr. Justin Mandel, DOM, is the Founder and CEO of EXOPYR, LLC, and creator of the Extinguish Inflammation® protocol, a breakthrough concierge health framework redefining how inflammation is treated across the body’s four biological layers.
Recognized by PayPath.com as their “Pick to Watch,” Dr. Mandel’s mission is to improve the health and longevity of over one million people worldwide.
Before developing EXOPYR’s pioneering inflammation system, Dr. Mandel spent nearly three decades in the clinical field – a journey that began with his first clinical internship in 1997 and ultimately included more than 70,000 treatments personally performed. Drawing on decades of clinical observation, extensive research, and a deep investigation into his own systemic inflammation, he identified what conventional approaches often fail to address: inflammation operates across multiple interconnected levels – systemic, genetic, cellular, and repair – and no single intervention can address the entire system alone.
In addition to his clinical expertise, Dr. Mandel served as Chief Operating Officer and cofounder of Global Medical Innovations, LLC, a surgical medical device company established with a Harvard-trained physician. During his near-decade tenure, he helped lead the development, medical device design, and commercialization of innovations in post-surgical care. His career spans diagnostic and treatment innovation, medical device development, pain relief formulation, and digital health technology, all with one unifying goal — creating science-backed systems that restore function and extend vitality.
“From the Hamptons to boardrooms to Billionaire’s Row, Dr. Mandel understands the lifestyle of those who demand more – and he built Extinguish Inflammation to meet that standard.”
For additional background and credentials, Dr. Mandel’s professional profile is available on LinkedIn.
Whose bladder research Harvard found “intriguing”, now leading the next evolution in inflammation science.
A message on the future of inflammation medicine and EXOPYR’s mission to unify diagnostics, biology, and real-world recovery.
Almost two decades ago, my one-of-a-kind research on Overactive Bladder diagnosis and treatment led to findings Harvard researchers described as “intriguing.” That experience taught me something fundamental, that even the most localized dysfunctions are rarely local at all. Instead, they’re systemic reflections of the body’s deeper imbalances.
EXOPYR was founded to pursue that insight at scale – to develop a precision framework capable of supporting the body’s inflammatory response across every biological level, across interconnected inflammatory and metabolic processes, inherited biological considerations, cellular conditions, and mechanisms associated with recovery.
Every generation of medicine has its inflection point, a moment when the science finally catches up to what patients have been feeling for decades. We believe that moment arrived when inflammation itself became measurable and modifiable through data-driven support.
The 2025 Nobel Prize in Medicine recognized the principle of immune tolerance, the body’s natural ability to self-correct when regulation replaces suppression. At EXOPYR, we’ve drawn on that broader scientific context, integrating diagnostics, neuromodulation, and targeted nutraceutical therapeutics into a coherent holistic system designed to support biological balance and produce measurable data.
EXOPYR’s four-dimension framework considers systemic, genetic, cellular, and repair processes. Selected laboratory markers provide useful measurements over time, although the core panel does not directly test every process within those four dimensions. These are not isolated readings; they are living indicators of the body’s capacity to regulate itself.
What makes EXOPYR distinct is not a single compound or device. It’s the architecture, how each element interacts in sequence to coordinate physician-directed interventions within a four-dimension framework while measuring changes in selected inflammatory and metabolic biomarkers. Every nutraceutical in our Concierge Inflammation Kit is available individually, but it’s the precision of the formulation strategy – the way each element is selected, coordinated, and evaluated for the individual.
In clinical terms, we don’t just track symptoms; we track the underlying biology. That’s the central thesis of modern functional medicine, and EXOPYR embodies it at scale.
EXOPYR is building a physician-led clinical process in which laboratory findings, health history, and client experience will inform individualized recommendations that balances quantitative biomarkers with qualitative human experience. We measure what matters, verify results through repeat labs, and refine based on evidence, not ideology.
Our commitment is to clinical integrity, scientific transparency, and patient empowerment. The EXOPYR approach is designed to complement, not compete with, traditional care, by offering a biologically precise roadmap toward genuine resolution, not temporary suppression.
“The future of inflammation medicine is integration. And EXOPYR exists to build that bridge, from lab to life.”
Dr. Justin Mandel, DOM
Founder & Clinical Architect, EXOPYR
Creator of the Extinguish Inflammation® protocol
EXOPYR welcomes inquiries from journalists, producers, and conference organizers seeking insight into the future of inflammation science and wellness innovation.
EXOPYR is organizing its first Florida clinical cohort. Submit your interest to receive availability, evaluation details, and next steps when enrollment opens.
Applications reviewed within 24 hours.